The Motley Fool

Why AstraZeneca Plc Has Underperformed The FTSE 100 Over The Past Year

The share price of AstraZeneca (LSE: AZN) (NYSE: AZN.US) has seriously underperformed the FTSE 100 over the past year, rising only 8.5% compared to the index’s 14% gain.

So what’s going wrong? Well, the company has suffered from two main problems for several years now.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

The first is that many of its established products have seen their patents expire, meaning they could be manufactured by others and therefore could no longer command a premium price.

And the other problem is that the pipeline of potential new products has been running dry, meaning there have been no new ‘blockbuster’ treatments — those that generate £1bn or more of revenue a year — to replace the ones the blue chip has lost.

Encouraging news

But the past year has also seen some encouraging news coming from AstraZeneca.

At the end of August 2012, the company announced that Pascal Soriot would be its new chief executive officer. Soriot was previously chief operating officer of Roche, one of the industry’s most successful developers of new pharmaceutical products. AstraZeneca was clearly hoping that he’d bring much-needed expertise with him.

In January, Soriot shook up AstraZeneca’s senior management, removing superfluous layers to speed-up decision making, and giving a more prominent role to the R&D staff who essentially create the products that will generate the company’s long-term revenue.

And a couple of months later, Soriot unveiled a strategy intended to return the company to growth and to “achieve scientific leadership“, and made an “unambiguous commitment” to concentrate efforts and resources on AstaZeneca’s “priority growth platforms” and “priority pipeline projects“.

Strengthened pipeline

Then at the beginning of August this year, the company announced that its ailing product pipeline had been strengthened by the addition of three late-stage treatments in the firm’s core therapeutic areas of cardiovascular/metabolism and respiratory diseases.

If AstraZeneca can deliver on its new strategy, its shares, which are currently on a P/E of around 10 — well below the FTSE 100 average — could turn out to be something of a bargain. And while you wait for the growth to happen, there’s the comfort of a 6% dividend.

Super investor

That substantial dividend may be one reason that, despite its overall performance, AstraZeneca has remained a firm favourite of investment guru Neil Woodford,  who has a remarkable track record of picking winners.

If you want to know about the other dividend-paying blue chips that Woodford currently favours, get your copy of the FREE Motley Fool report, 8 Shares Held By Britain’s Super Investornow!

> Jon does not own any share mentioned in this article.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.